Search | Clinical Trials Finder

Conditions: Influenza and Other Novel Respiratory Viruses
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 11,719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 17
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more

Conditions: Pandemic H5N1 Influenza
Interventions: Adjuvanted H5N1 pandemic influenza vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 979 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • St Louis, Missouri • Austin, Texas

Conditions: Influenza A Virus, H1N1 Subtype, Novel Swine-Origin
Interventions: VRC-FLUDNA057-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more

Conditions: Grippe, Influenza, Vaccines
Interventions: pdmFlu vaccine, Placebo, Licensed influenza vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: New Haven, Connecticut • Hollywood, Florida • New York, New York

Conditions: Influenza Immunization
Interventions: Pandemic flu H5 mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more

Conditions: Influenza, Virus Diseases
Interventions: Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Oseltamivir, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 100
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 91 more

Conditions: Influenza, Human
Interventions: zanamivir aqueous solution; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more

Conditions: Influenza
Interventions: GSK Biologicals' FluLaval®, Placebo (saline), GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina

Conditions: Influenza A Subtype H5N1 Infection
Interventions: Pandemic Influenza Vaccine, Placebo; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Avian Influenza, Immunisation
Interventions: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 adjuvant; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 47 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: behaviors reducing spread of influenza; Behavioral
Lead sponsor: Kiren Mitruka; Federal
Eligibility: 6 Months and older
Enrollment: 3,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Influenza, Pandemic
Interventions: BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM; Biological
Lead sponsor: BlueWillow Biologics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Avian Influenza
Interventions: aH5N1c, Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 3,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 26
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more

Conditions: Influenza A Virus Infection
Interventions: H2N3 MO 2003/AA ca Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 42 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: mRNA-1018-H5, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: San Bernardino, California • Savannah, Georgia • Meridian, Idaho + 7 more

Conditions: Influenza
Interventions: Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more

Conditions: Influenza
Interventions: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more

Conditions: Influenza Prevention, Pandemic Influenza Prevention
Interventions: VRC-FLUMOS0122-00-VP, ALFQ; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza A
Interventions: AZD4117, AZD5315, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Long Beach, California • Rolling Hills Estates, California • Miami Lakes, Florida + 11 more

Conditions: Pandemic H5N1 Influenza
Interventions: Adjuvanted H5N1 pandemic influenza vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 662 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Miami, Florida • Newton, Kansas • Wichita, Kansas + 6 more

Conditions: Influenza, Human
Interventions: ARCT-2304, Control vaccine younger adults, Control vaccine older adults, Placebo Vaccine; Biological · Other
Lead sponsor: Arcturus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: La Mesa, California • San Bernardino, California • Longmont, Colorado + 1 more

Search by objective public record fields.

Respiratory Virus Outpatient Study (FLU 002 Plus)

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Project to Investigate Ways to Reduce the Spread of Influenza in Schools and Households With Children

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults